Open AccessOnce-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
Author(s) -
Michael Fried,
Marı́a Buti,
Gregory J. Dore,
Robert Flisiak,
Péter Ferenci,
Ira M. Jacobson,
Patrick Marcellin,
Michael P. Manns,
Igor Nikitin,
Fred Poordad,
Morris Sherman,
Stefan Zeuzem,
Jane Scott,
Leen Gilles,
Oliver Lenz,
Monika Peeters,
Vanitha Sekar,
Goedele De Smedt,
Maria Beumont-Mauviel
Publication year - 2013
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/wfr0-7y45
Subject(s) - ribavirin , simeprevir , pegylated interferon , hepatitis c , genotype , virology , medicine , randomized controlled trial , pillar , hepatitis c virus , gastroenterology , biology , gene , genetics , virus , structural engineering , engineering
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom